Toll Free: 1-888-928-9744

Gallbladder Cancer - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gallbladder Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gallbladder Cancer.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gallbladder Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Gallbladder Cancer - Overview 7 Pipeline Products for Gallbladder Cancer - Comparative Analysis 8 Gallbladder Cancer - Therapeutics under Development by Companies 9 Gallbladder Cancer - Therapeutics under Investigation by Universities/Institutes 10 Gallbladder Cancer - Pipeline Products Glance 11 Clinical Stage Products 11 Gallbladder Cancer - Products under Development by Companies 12 Gallbladder Cancer - Products under Investigation by Universities/Institutes 13 Gallbladder Cancer - Companies Involved in Therapeutics Development 14 4SC AG 14 harma Inc 14 BeiGene Ltd 16 Eli Lilly and Company 17 Novartis AG 18 VasGene Therapeutics Inc 19 Gallbladder Cancer - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 BGBA-317 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 binimetinib - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 copanlisib hydrochloride - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 DKN-01 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 merestinib - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ramucirumab - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 resminostat - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 trametinib dimethyl sulfoxide - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Vas-01 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Gallbladder Cancer - Dormant Projects 71 Gallbladder Cancer - Discontinued Products 72 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Number of Products under Development for Gallbladder Cancer, H2 2016 7 Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Products under Investigation by Universities/Institutes, H2 2016 13 Gallbladder Cancer - Pipeline by 4SC AG, H2 2016 14 Gallbladder Cancer - Pipeline by Array BioPharma Inc, H2 2016 15 Gallbladder Cancer - Pipeline by Bayer AG, H2 2016 15 Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2016 16 Gallbladder Cancer - Pipeline by Eli Lilly and Company, H2 2016 17 Gallbladder Cancer - Pipeline by Novartis AG, H2 2016 18 Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Gallbladder Cancer - Dormant Projects, H2 2016 71 Gallbladder Cancer - Discontinued Products, H2 2016 72



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify